European antibiotic overuse persists despite awareness, while new treatment approaches emerge for cancer, liver disease, and pregnancy complications, alongside debates over emerging therapies like ibogaine.

European healthcare systems struggle with entrenched antibiotic overuse despite awareness efforts, with barriers ranging from pharmacists facing dispensing pressures in Romania to GPs in Malta fearing litigation when restricting prescriptions.

A subcutaneous ICD scoring system may safely eliminate the need for routine defibrillation testing during implantation by accurately evaluating device positioning and implant technique, potentially reducing procedural complications.

Primary care physicians are increasingly expected to manage metabolic dysfunction-associated fatty liver disease (MASH) using noninvasive testing as liver disease prevalence rises alongside diabetes and obesity epidemics.

A GOSH-led trial demonstrates that replacing intensive chemotherapy with blinatumomab in relapsed childhood acute lymphoblastic leukemia eliminates treatment-related deaths while maintaining overall survival rates.

Adjuvant pembrolizumab improves distant metastasis-free survival in resectable Merkel cell carcinoma patients following surgical resection, though broader overall survival benefits remain under investigation.

Ibogaine is receiving accelerated federal research funding for addiction treatment despite being unapproved and understudied, raising safety concerns over documented risks of fatal cardiac arrhythmias.

Home blood pressure monitoring in high-risk pregnancies matches standard clinical care outcomes while reducing clinic visits and hospitalizations, offering a more convenient care model for expectant mothers.

A new investigational osteoarthritis drug shows promise as a non-NSAID analgesic alternative, potentially avoiding the long-term gastrointestinal and cardiovascular risks associated with traditional nonsteroidal anti-inflammatory medications.